FGFR1 and adenocarcinoma: Increased FGFR1 expression is frequent across various lung cancer histologies, including squamous cell carcinomas (SCC) (~25%), and adenocarcinomas (~15%), and FGFR inhibitors (FGFRi) are currently being evaluated in patients with lung SCC and other malignancies18–22.